>Maybe this is a dumb question, but I was wondering why Teva can't simply launch a branded generic [Copaxone] of their own. They certainly have the experience and the infrastructure.<
They can and they probably will at some point. But there will still be only two Copaxone players in the market, which implies relatively high prices.
Market Data 
Markets 
AI
